<DOC>
	<DOC>NCT02608242</DOC>
	<brief_summary>This is a Randomized, open-label, single-dose, 3-treatment, 3-period, 3-sequence crossover design.</brief_summary>
	<brief_title>PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin</brief_title>
	<detailed_description>This is a 6 by 3 cross-over study to evaluate pharmacokinetics of YH22189 FDC compared to reference telmisartan/amlodipine and rosuvastatin co-administered in three groups enrolling healthy adult male subjects under fasting conditions. Subjects will be admitted to the clinic in the evening before Day 1. All subjects will receive a single oral dose of YH22189 FDC or telmisartan/amlodipine or rosuvastatin administered in the morning on Day 1. All the subjects will remain in the clinical unit until completion of all assessments on Day 2 including collection post-dose PK sample. Subjects will return to the clinic for pharmacokinetic samples at scheduled time. The three treatment periods will be separated by a washout period.</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Healthy male and female with a body mass index(BMI) between 18.5 and 25 kg/m2 Who has not suffered from clinically significant disease Provision of signed written informed consent History of and clinically significant disease A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs Administration of other investigational products within 3 months prior to the first dosing Volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ECGs, or vital signs Sitting blood pressure meeting the following criteria at screening: 150 ≥ systolic blood pressure ≤100 (mmHg) and 100 ≥ diastolic blood pressure ≤ 60 (mmHg)</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>